These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

126 related items for PubMed ID: 21108438

  • 1. Octreotide acetate is efficacious and safe in children for treating diarrhea due to chemotherapy but not acute graft versus host disease.
    Pai V, Porter K, Ranalli M.
    Pediatr Blood Cancer; 2011 Jan; 56(1):45-9. PubMed ID: 21108438
    [Abstract] [Full Text] [Related]

  • 2. Octreotide in the management of diarrhea induced by graft versus host disease.
    Ippoliti C, Neumann J.
    Oncol Nurs Forum; 1998 Jun; 25(5):873-8. PubMed ID: 9644703
    [Abstract] [Full Text] [Related]

  • 3. A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.
    Rosenoff SH, Gabrail NY, Conklin R, Hohneker JA, Berg WJ, Warsi G, Maloney J, Benedetto JJ, Miles EA, Zhu W, Anthony L.
    J Support Oncol; 2006 Jun; 4(6):289-94. PubMed ID: 16805331
    [Abstract] [Full Text] [Related]

  • 4. Octreotide LAR resolves severe chemotherapy-induced diarrhoea (CID) and allows continuation of full-dose therapy.
    Rosenoff SH.
    Eur J Cancer Care (Engl); 2004 Sep; 13(4):380-3. PubMed ID: 15305907
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of octreotide in controlling refractory diarrhea following bone marrow transplantation.
    Morton AJ, Durrant ST.
    Clin Transplant; 1995 Jun; 9(3 Pt 1):205-8. PubMed ID: 7549062
    [Abstract] [Full Text] [Related]

  • 6. Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies.
    Ippoliti C, Champlin R, Bugazia N, Przepiorka D, Neumann J, Giralt S, Khouri I, Gajewski J.
    J Clin Oncol; 1997 Nov; 15(11):3350-4. PubMed ID: 9363865
    [Abstract] [Full Text] [Related]

  • 7. Gastrointestinal toxicity from the preparative regimen is associated with an increased risk of graft-versus-host disease.
    Goldberg J, Jacobsohn DA, Zahurak ML, Vogelsang GB.
    Biol Blood Marrow Transplant; 2005 Feb; 11(2):101-7. PubMed ID: 15682070
    [Abstract] [Full Text] [Related]

  • 8. Octreotide (SMS 201-995) for hematopoietic support-dependent high-dose chemotherapy (HSD-HDC)-related diarrhoea: dose finding study and evaluation of efficacy.
    Wasserman E, Hidalgo M, Hornedo J, Cortés-Funes H.
    Bone Marrow Transplant; 1997 Nov; 20(9):711-4. PubMed ID: 9384471
    [Abstract] [Full Text] [Related]

  • 9. Octreotide in the management of chemoradiotherapy-induced diarrhea refractory to loperamide in patients with rectal carcinoma.
    Topkan E, Karaoglu A.
    Oncology; 2006 Nov; 71(5-6):354-60. PubMed ID: 17873499
    [Abstract] [Full Text] [Related]

  • 10. Resolution of refractory chemotherapy-induced diarrhea (CID) with octreotide long-acting formulation in cancer patients: 11 case studies.
    Rosenoff S.
    Support Care Cancer; 2004 Aug; 12(8):561-70. PubMed ID: 15160318
    [Abstract] [Full Text] [Related]

  • 11. Octreotide in chemotherapy induced diarrhoea in colorectal cancer: a review article.
    Bhattacharya S, Vijayasekar C, Worlding J, Mathew G.
    Acta Gastroenterol Belg; 2009 Aug; 72(3):289-95. PubMed ID: 19902860
    [Abstract] [Full Text] [Related]

  • 12. Octreotide Acetate in the Treatment of Fluorouracil-Induced Diarrhea.
    Goumas P, Naxakis S, Christopoulou A, Chrysanthopoulos C, Nikolopoulou V, Kalofonos HP.
    Oncologist; 1998 Aug; 3(1):50-53. PubMed ID: 10388084
    [Abstract] [Full Text] [Related]

  • 13. Management of cancer treatment-related diarrhea. Issues and therapeutic strategies.
    Kornblau S, Benson AB, Catalano R, Champlin RE, Engelking C, Field M, Ippoliti C, Lazarus HM, Mitchell E, Rubin J, Stiff PJ, Vokes E, Wadler S.
    J Pain Symptom Manage; 2000 Feb; 19(2):118-29. PubMed ID: 10699539
    [Abstract] [Full Text] [Related]

  • 14. Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea.
    Wadler S, Haynes H, Wiernik PH.
    J Clin Oncol; 1995 Jan; 13(1):222-6. PubMed ID: 7799023
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Clinical implications of chemotherapy-induced diarrhea in patients with cancer.
    Arnold RJ, Gabrail N, Raut M, Kim R, Sung JC, Zhou Y.
    J Support Oncol; 2005 Jan; 3(3):227-32. PubMed ID: 15915825
    [Abstract] [Full Text] [Related]

  • 20. Use of a somatostatin analogue, octreotide acetate, in the management of acute gastrointestinal graft-versus-host disease.
    Ely P, Dunitz J, Rogosheske J, Weisdorf D.
    Am J Med; 1991 Jun; 90(6):707-10. PubMed ID: 2042686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.